doxepin has been researched along with Bigfoot Disease in 2 studies
Doxepin: A dibenzoxepin tricyclic compound. It displays a range of pharmacological actions including maintaining adrenergic innervation. Its mechanism of action is not fully understood, but it appears to block reuptake of monoaminergic neurotransmitters into presynaptic terminals. It also possesses anticholinergic activity and modulates antagonism of histamine H(1)- and H(2)-receptors.
doxepin : A dibenzooxepine that is 6,11-dihydrodibenzo[b,e]oxepine substituted by a 3-(dimethylamino)propylidene group at position 11. It is used as an antidepressant drug.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, KR | 1 |
| Bershow, A | 1 |
| Crowson, AN | 1 |
| Sollecito, TP | 1 |
| DeRossi, S | 1 |
| Stewart, JC | 1 |
| Ettlin, D | 1 |
| Mowad, C | 1 |
2 other studies available for doxepin and Bigfoot Disease
| Article | Year |
|---|---|
Elephantiasis nostras verrucosa secondary to scleroderma.
Topics: Anti-Bacterial Agents; Bandages; Biopsy; Cephalexin; Dermatologic Agents; Doxepin; Elephantiasis; Fe | 2019 |
Elephantiasis nostras of the lips: a case report.
Topics: Adult; Anti-Bacterial Agents; Antipruritics; Bacterial Infections; Clindamycin; Connective Tissue; D | 1997 |